These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31043468)

  • 61. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
    Hsueh PR; Chen WH; Luh KT
    Int J Antimicrob Agents; 2005 Dec; 26(6):463-72. PubMed ID: 16280243
    [TBL] [Abstract][Full Text] [Related]  

  • 63. In vitro activity of aryl fluoroquinolones, Abbott 56619 and Abbott 56620, compared to ciprofloxacin, norfloxacin and beta-lactams versus multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Meyer RD; Liu S
    Chemotherapy; 1986; 32(5):425-30. PubMed ID: 3093154
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
    Roveta S; Schito AM; Marchese A; Schito GC
    Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Fluoroquinolone and aminoglycoside resistance in chromosomal cephalosporinase-overproducing gram-negative bacilli strains with inducible beta-lactamase].
    López-Yeste M; Xercavins M; Lite J; Cuchí E; Garau J
    Enferm Infecc Microbiol Clin; 1996 Apr; 14(4):211-4. PubMed ID: 9044634
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M; García-Castillo M; Bofarull AM; Cantón R;
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.
    Carvalhaes CG; Castanheira M; Sader HS; Flamm RK; Shortridge D
    Diagn Microbiol Infect Dis; 2019 May; 94(1):93-102. PubMed ID: 30642717
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evaluating outcomes associated with revised fluoroquinolone breakpoints for Enterobacterales urinary tract infections: A retrospective cohort study.
    Benavides TM; Aden JK; Giancola SE
    Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):741-749. PubMed ID: 35224677
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of outpatient antibiotics for urinary tract infections on antimicrobial resistance among commensal Enterobacteriaceae: a multinational prospective cohort study.
    Stewardson AJ; Vervoort J; Adriaenssens N; Coenen S; Godycki-Cwirko M; Kowalczyk A; Huttner BD; Lammens C; Malhotra-Kumar S; Goossens H; Harbarth S; ;
    Clin Microbiol Infect; 2018 Sep; 24(9):972-979. PubMed ID: 29331548
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The quest for the best metric of antibiotic use and its correlation with the emergence of fluoroquinolone resistance in children.
    Rose L; Coulter MM; Chan S; Hossain J; Di Pentima MC
    Pediatr Infect Dis J; 2014 Jun; 33(6):e158-61. PubMed ID: 24830523
    [TBL] [Abstract][Full Text] [Related]  

  • 71.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli.
    Sader HS; Huynh HK; Jones RN
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):547-50. PubMed ID: 14596974
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cefazolin and enterobacteriaceae: rationale for revised susceptibility testing breakpoints.
    Turnidge JD;
    Clin Infect Dis; 2011 Apr; 52(7):917-24. PubMed ID: 21427400
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model.
    Mikuniya T; Kato Y; Ida T; Maebashi K; Monden K; Kariyama R; Kumon H
    J Infect Chemother; 2007 Oct; 13(5):285-90. PubMed ID: 17982715
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Adoption of the updated CLSI fluoroquinolone breakpoints for Gram-negative bacteria in microbiology laboratories.
    Sfeir MM
    Clin Microbiol Infect; 2021 Feb; 27(2):308-310. PubMed ID: 32717418
    [No Abstract]   [Full Text] [Related]  

  • 77. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints.
    Kahlmeter G
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():169-74. PubMed ID: 18154542
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013.
    Jean SS; Coombs G; Ling T; Balaji V; Rodrigues C; Mikamo H; Kim MJ; Rajasekaram DG; Mendoza M; Tan TY; Kiratisin P; Ni Y; Weinman B; Xu Y; Hsueh PR
    Int J Antimicrob Agents; 2016 Apr; 47(4):328-34. PubMed ID: 27005459
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The newer fluoroquinolones.
    Bolon MK
    Infect Dis Clin North Am; 2009 Dec; 23(4):1027-51, x. PubMed ID: 19909896
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates.
    Rutter WC; Burgess DR; Burgess DS
    Microb Drug Resist; 2017 Jan; 23(1):51-55. PubMed ID: 27326758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.